» Articles » PMID: 30259274

Dangers of Overly Aggressive Blood Pressure Control

Overview
Publisher Current Science
Date 2018 Sep 28
PMID 30259274
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Recent US guidelines have changed the definition of hypertension to ≥ 130/80 mmHg and recommended more intense blood pressure (BP) targets. We summarize the evidence for intense BP treatment and discuss risks that must be considered when choosing treatment goals for individual patients.

Recent Findings: The SPRINT study reported that treating to a systolic BP target of 120 mmHg reduces cardiovascular outcomes in high-risk individuals, supporting more intensive BP reduction than previously recommended. However, recent observational studies have placed emphasis on the BP J-curve phenomenon, where low BPs are associated with adverse cardiovascular outcomes, suggesting that overly aggressive BP targets may sometimes be harmful. We attempt to reconcile these apparent contradictions for the clinician. We also review other potential dangers of aggressive BP targets, including syncope, renal impairment, polypharmacy, drug interactions, subjective drug side-effects, and non-adherence. We suggest a personalized approach to BP drug management considering individual risks, benefits, and preferences when choosing therapeutic targets, recognizing that a goal of 130/80 mmHg should always be considered. Additionally, we recommend an intense focus on lifestyle changes and medication adherence.

Citing Articles

The role of brain natriuretic peptide in atrial fibrillation: a substudy of the Substrate Modification with Aggressive Blood Pressure Control for Atrial Fibrillation (SMAC-AF) trial.

Weng W, Choudhury R, Sapp J, Tang A, Healey J, Nault I BMC Cardiovasc Disord. 2021; 21(1):445.

PMID: 34530738 PMC: 8447763. DOI: 10.1186/s12872-021-02254-5.


Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus.

Rahman F, McEvoy J, Ohkuma T, Marre M, Hamet P, Harrap S Hypertension. 2019; 73(6):1291-1299.

PMID: 31030606 PMC: 6506385. DOI: 10.1161/HYPERTENSIONAHA.118.12414.

References
1.
Tinetti M, Han L, Lee D, McAvay G, Peduzzi P, Gross C . Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med. 2014; 174(4):588-95. PMC: 4136657. DOI: 10.1001/jamainternmed.2013.14764. View

2.
Beddhu S, Chertow G, Cheung A, Cushman W, Rahman M, Greene T . Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control. Circulation. 2017; 137(2):134-143. PMC: 5760457. DOI: 10.1161/CIRCULATIONAHA.117.030848. View

3.
Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M . Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2010; 34(1):87-90. DOI: 10.1038/hr.2010.183. View

4.
Staessen J, Fagard R, Thijs L, Celis H, Arabidze G, Birkenhager W . Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997; 350(9080):757-64. DOI: 10.1016/s0140-6736(97)05381-6. View

5.
Cushman W, Evans G, Byington R, Goff Jr D, Grimm Jr R, Cutler J . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1575-85. PMC: 4123215. DOI: 10.1056/NEJMoa1001286. View